|1.||Squadrito, F: 3 articles (03/2007 - 03/2001)|
|2.||Altavilla, D: 3 articles (03/2007 - 03/2001)|
|3.||Altavilla, Domenica: 3 articles (07/2005 - 10/2004)|
|4.||Bitto, Alessandra: 3 articles (07/2005 - 10/2004)|
|5.||Squadrito, Francesco: 3 articles (07/2005 - 10/2004)|
|6.||Calò, Margherita: 2 articles (07/2005 - 04/2005)|
|7.||Minutoli, Letteria: 2 articles (07/2005 - 04/2005)|
|8.||Squadrito, Giovanni: 2 articles (07/2005 - 04/2005)|
|9.||Seminara, Paolo: 2 articles (07/2005 - 04/2005)|
|10.||Marini, Herbert: 2 articles (04/2005 - 10/2004)|
|1.||Wounds and Injuries (Trauma)
04/01/2001 - "The administration of raxofelast did not modify the process of wound repair in healthy (db/+) mice, but significantly improved impaired wound healing in diabetic mice through the stimulation of angiogenesis, reepithelialization, synthesis, and maturation of extracellular matrix. "
03/01/2001 - "Administration of raxofelast did not modify the process of wound repair in normal mice, but significantly improved the impaired wound healing in diabetic mice through the stimulation of angiogenesis, re-epithelization, and synthesis and maturation of extracellular matrix. "
04/01/2001 - "The current study provides evidence that raxofelast restores wound healing to nearly normal levels in experimental diabetes-impaired wounds and suggests that an increased lipid peroxidation in diabetic mice may have a role in determining a defect of wound repair."
04/01/2001 - "The wound healing effect of raxofelast was investigated by using an incisional skin-wound model produced on the back of female diabetic C57BL/KsJ db+/db+ mice and their healthy littermates (db+/+m). "
03/01/2001 - "Moreover, raxofelast treatment significantly reduced wound CD levels and increased the breaking strength of the wound. "
01/01/1999 - "2. In vivo treatment with raxofelast (5, 10, 20 mg kg(-1) intraperitoneally 5 min before carrageenan) prevented in a dose dependent manner carrageenan-induced pleural exudation and polymorphonuclear migration in rats subjected to carrageenan-induced pleurisy. "
01/01/1999 - "Here we have investigated the therapeutic efficacy of raxofelast, a new hydrophilic vitamin E-like antioxidant agent, in rats subjected to carrageenan-induced pleurisy. "
01/01/1999 - "4. Furthermore, in vivo raxofelast (5, 10, 20 mg kg(-1)) treatment significantly reduced peroxynitrite formation as measured by the oxidation of the fluorescent dihydrorhodamine 123, prevented the appearance of DNA damage, the decrease in mitochondrial respiration and partially restored the cellular level of NAD+ in ex vivo macrophages harvested from the pleural cavity of rats subjected to carrageenan-induced pleurisy. "
01/01/1999 - "Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy."
|4.||Liver Diseases (Liver Disease)
01/26/2004 - "The antioxidant activity of raxofelast has been convincingly demonstrated in several in vitro studies and in various models of ischemia-reperfusion injury. "
03/01/2007 - "Raxofelast, (+/-)5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acid: a new antioxidant to modulate the inflammatory response during ischemia-reperfusion injury and impaired wound healing."
10/01/2004 - "Raxofelast, a hydrophilic vitamin E-like antioxidant, reduces testicular ischemia-reperfusion injury."
08/01/1998 - "Beneficial effect of raxofelast, an hydrophilic vitamin E analogue, in the rat heart after ischemia and reperfusion injury."
|4.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Peroxynitrous Acid (Peroxynitrite)
|6.||Acetic Acid (Vinegar)